Bridging deep sequencing to precision oncology in meningiomas
Bridging deep sequencing to precision oncology in meningiomas
复制标题
将深度测序与脑膜瘤精准肿瘤学联系起来
DOI：
10.1093/neuonc/noad004
复制
发表时间：
2023
期刊：
影响因子：
15.9
通讯作者：
Chunsheng Kang
中科院分区：
文献类型：
--
作者：
Xing Liu;Chunsheng Kang
当涉及到预测临床结果和治疗脆弱性时，传统的组织学特征和分级方案遇到越来越多的挑战。近几十年来，多维分子数据增强了我们对中枢神经系统肿瘤的理解，使其能够进行更精确的诊断和定制治疗的潜力。例如，胶质母细胞瘤，其在历史上仅基于组织学标准诊断，现在被定义为具有组织学或遗传特征的IDH-野生型和H3-野生型弥漫性胶质瘤，并且可以基于DNA甲基化、转录组学和蛋白质组学数据进一步细分。核心通路的基因改变，如EGFR和MET，可能为此类患者提供有希望的治疗靶点。2
When it comes to predicting clinical outcomes and therapeutic vulnerabilities, conventional histological features and grading schemes encounter increasing challenges. In recent decades, multidimensional molecular data have enhanced our understanding of central nervous system tumors, enabling for more precise diagnosis and the potential of tailored therapy. For instance, glioblastoma, which was historically diagnosed solely based on histological criteria, is now defined as IDH-wildtype and H3-wildtype diffused gliomas with either histological or genetic characteristics, and could be further subdivided based on DNA methylation, transcriptomic, and proteomic data. 1 Genetic alterations in core pathways, such as EGFR and MET, may provide promising treatment targets for such patients. 2